<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23865">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796105</url>
  </required_header>
  <id_info>
    <org_study_id>BRAKE</org_study_id>
    <nct_id>NCT02796105</nct_id>
  </id_info>
  <brief_title>Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Privada Eugin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Privada Eugin</source>
  <brief_summary>
    <textblock>
      Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus
      GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>donor ovarian response</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Progevera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progevera 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orgalutran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orgalutran 0.25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progevera</intervention_name>
    <arm_group_label>Progevera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orgalutran</intervention_name>
    <arm_group_label>Orgalutran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Oocyte donors included in the oocyte donation program of Clinica EUGIN.

          -  1st oocyte donation cycle at Clínica EUGIN.

        Exclusion Criteria:

          -  Polycistic Ovarian syndrome (PCOs).

          -  Estradiol levels on day 2 of menstrual cycle &gt;70 pg/ml.

          -  Hormone treatments up to 3 months before the oocyte donation cycle.

          -  Medical contraindication to the treatments used in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebeca Begueria, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Eugin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Désirée García</last_name>
    <phone>0034933221122</phone>
    <email>fundacio@eugin.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Eugin</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Begueria, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 9, 2016</lastchanged_date>
  <firstreceived_date>June 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
